He also received research funding from TGen Clinical Research. D Von Hoff: is a consultant/advisor to Celgene and has received honoraria from them. Samuel is an expert on MPC with over a decade of research in the field. Penenberg: Owns stock in Celgene and is a Celgene employee D. Samuel Ranellucci is a full-time cryptographer at Unbound Security. Lu: is an employee of Celgene and owns stock D. Stahl: I am an advisor to Celgene and receive honoraria B. Ma: has received research funding and honoraria from Celgene M. No new safety signals were observed.ĭisclosure: W.W. These findings are consistent with previous efficacy findings in the ITT population from MPACT. This effect remained clinically and statistically significant regardless of the primary tumor location. The most common grade ≥ 3 adverse events in pts with pancreatic head tumors for nab-P + Gem vs Gem (neutropenia, peripheral neuropathy, and fatigue ) were similar to those in the intent-to-treat (ITT) population.Ĭonclusions: nab-P + Gem demonstrated superior efficacy vs Gem alone. Martin Vogt is CEO of MPC Energy Solutions and at the same time a Managing Director at MPC Capital with overall management responsibility of the group’s global renewable energy activities. The median cumulative dose of nab-P was 1500 mg/m 2 vs 1375 mg/m 2 in pts who had primary tumors in the head vs tail or body. Tumor location did not appear to be associated with any differences in treatment exposure. 1.1.0 and user documentation (revA-EN) VC-Dot 1 White Personality Files VC-Dot 4 White Personality Files VC-Dot 9 White Personality Files VC-Strip White Personality Files Note: some browsers hide scrollbars until you begin scrolling. Results: nab-P + Gem demonstrated superior survival vs Gem alone, independent of the primary tumor location (Table). In this analysis, OS, PFS, and treatment exposure were analyzed according to primary tumor location. Methods: Previously untreated pts (N = 861) with MPC and baseline bilirubin ≤ upper limit of normal were randomized 1:1 to receive nab-P 125 mg/m 2 + Gem 1000 mg/m 2 on d 1, 8, and 15 of each 28-d cycle or Gem 1000 mg/m 2 weekly for 7 wk followed by 1 wk of rest (cycle 1) and then d 1, 8, and 15 of each 28-d cycle (cycle ≥ 2).
The effect of primary pancreatic tumor location on efficacy and treatment exposure in the MPACT trial is reported. In the phase III MPACT trial, nab-P + Gem demonstrated superior efficacy vs Gem alone as first-line treatment for MPC (median overall survival : 8.5 vs 6.7 mo hazard ratio 0.72 P < 0.001 median progression-free survival, 5.5 vs 3.7 mo HR 0.69 P < 0.001).
Aim: The prognosis of pancreatic cancer may be influenced by the primary tumor location within the pancreas.